Myriad will use its BRACAnalysis test to detect mutations in breast cancer 1 early onset (BRCA1) and BRCA2 genes in patients to be enrolled in BioMarin's ongoing Phase I/II trial evaluating BMN-673

BioMarin Pharmaceutical Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Myriad Genetics Inc.

U.S. / Medical Devices and Diagnostics

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced